Single-dose daclizumab induction therapy in patients with liver transplantation.
OBJECTIVE
To investigate the efficacy and safety of a single-dose daclizumab induction therapy in orthotopic liver transplantation (OLTx).


METHODS
A retrospective study was made for 54 cases of OLTx in recent three years. The daclizumab group consisted of 23 cases of OLTx who received single-dose of 2 mg/kg intravenously after postoperative 24 hours. The control group consisted of the remaining 31 patients. Additional immunosuppressors included steroids, mycomphenolate mofetil, facrolimus or microemulsion cyclosporine used in all patients. Meta-statistical analysis was made for general data, incidence of acute rejection and infection, postoperative clinical course, complications and prognosis between two groups.


RESULTS
Pretransplant demographies were not significantly different between two groups. In the induction group there were significantly less acute rejection episodes (5 of 23, 21.74 %) than those in the control group (12 of 31, 38.71 %), which were proved by pathologic diagnosis (P<0.05). The incidence of infection at the early stage was not significantly different between two groups.


CONCLUSIONS
Induction therapy with single-dose of daclizumab is safe and effective and appears to be able to reduce the incidence of acute rejection.
Yan
Lu-Nan
LN
Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China. yanlunan@hotmail.com
Wang
Wei
W
Li
Bo
B
Lu
Shi-Chun
SC
Wen
Tian-Fu
TF
Lin
Qi-Yuan
QY
Zeng
Yong
Y
Cheng
Nan-Sheng
NS
Zhao
Ji-Chun
JC
Dai
Yue-Meng
YM
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000077561:Daclizumab; D004334:Drug Administration Schedule; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage*; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D007275:Injections, Intravenous; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D011182:Postoperative Care; D012189:Retrospective Studies
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D000077561:Daclizumab